This inventor holds 6 USPTO granted patents. Top assignees: University of Utah Research Foundation, The Salk Institute, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.. Active years: 1997-1999.
Location History:
- Salt Lake City, UT (US) (1997 - 1998)
- Shaker Heights, OH (US) (1998 - 1999)
Company Filing History:
6 out of 1,685 
1 out of 593 
1 out of 911 
Years Active: 1997-1999
Title: Ki-Joon Shon: Innovator in Conotoxin Peptides
Introduction
Ki-Joon Shon is a prominent inventor based in Salt Lake City, UT (US). He has made significant contributions to the field of biochemistry, particularly in the development of conotoxin peptides. With a total of 6 patents, his work has implications for both medical research and therapeutic applications.
Latest Patents
One of Ki-Joon Shon's latest patents focuses on conotoxin peptides that consist of 25-35 amino acids and feature six cysteines forming three disulfide bonds. This invention includes .delta.-conotoxin GmVIA, which activates sodium channels, and .mu.O-conotoxin peptides that block sodium channels. These peptides are designed to inhibit synaptic transmissions at neuromuscular junctions, specifically targeting certain skeletal nAChRs while excluding neuronal nAChRs. The peptides can be synthesized chemically, making them valuable for both in vivo applications and laboratory assays.
Career Highlights
Throughout his career, Ki-Joon Shon has worked with esteemed institutions such as the University of Utah Research Foundation and The Salk Institute. His research has advanced the understanding of conotoxin peptides and their potential therapeutic uses.
Collaborations
Ki-Joon Shon has collaborated with notable scientists, including Baldomero M Olivera and Doju Yoshikami. These partnerships have contributed to the depth and breadth of his research in the field of conotoxin peptides.
Conclusion
Ki-Joon Shon is a distinguished inventor whose work on conotoxin peptides has opened new avenues in medical research. His innovative contributions continue to impact the scientific community and hold promise for future therapeutic applications.